Q1 Earnings Forecast for MDxHealth Issued By William Blair

MDxHealth SA (NASDAQ:MDXH - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of MDxHealth in a research note issued to investors on Wednesday, February 26th. William Blair analyst A. Brackmann anticipates that the company will earn ($0.13) per share for the quarter. The consensus estimate for MDxHealth's current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth's Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.07) EPS and Q4 2026 earnings at ($0.05) EPS.

Separately, Piper Sandler decreased their price objective on shares of MDxHealth from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Thursday, November 7th.

MDxHealth Stock Down 4.1 %

Shares of NASDAQ MDXH traded down $0.07 during mid-day trading on Friday, reaching $1.64. The company had a trading volume of 176,382 shares, compared to its average volume of 85,455. The firm has a 50 day simple moving average of $1.99 and a two-hundred day simple moving average of $2.18. MDxHealth has a 52-week low of $1.55 and a 52-week high of $3.85. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The stock has a market cap of $77.55 million, a P/E ratio of -1.08 and a beta of 1.34.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million.

Remove Ads

Institutional Investors Weigh In On MDxHealth

Several large investors have recently modified their holdings of the company. AWM Investment Company Inc. raised its position in MDxHealth by 11.1% in the 4th quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock valued at $11,189,000 after purchasing an additional 471,290 shares during the last quarter. MVM Partners LLC raised its holdings in shares of MDxHealth by 3.3% in the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company's stock valued at $9,706,000 after buying an additional 150,000 shares during the last quarter. Samjo Management LLC boosted its stake in shares of MDxHealth by 130.9% during the fourth quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock worth $4,324,000 after buying an additional 1,034,312 shares during the period. Perkins Capital Management Inc. grew its holdings in shares of MDxHealth by 31.6% during the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock worth $2,331,000 after buying an additional 236,100 shares during the last quarter. Finally, Northern Trust Corp acquired a new position in MDxHealth in the 4th quarter valued at about $1,033,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.